2002:TWSETELCON RF PHARMACEUTICAL. Inc. Analysis
Data as of 2026-03-11 - not real-time
₩758.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TELCON RF PHARMACEUTICAL is trading well below its short‑, medium‑, and long‑term moving averages, signaling a pronounced bearish price trend. The RSI has slipped below the 40 threshold, hinting at oversold conditions, while the MACD remains in a bearish configuration with a negative histogram. Support sits near 685 KRW and resistance near 945 KRW, with the current price comfortably above support but still far from resistance.
Fundamentally, the company posts robust revenue growth and a sizable cash pile, yet it struggles with negative profitability, a weak operating cash flow, and an extremely high debt‑to‑equity ratio. A discounted cash‑flow model values the stock at roughly four times its market price, indicating potential undervaluation, but the absence of earnings, dividends, and a volatile price history amplify the risk profile.
Fundamentally, the company posts robust revenue growth and a sizable cash pile, yet it struggles with negative profitability, a weak operating cash flow, and an extremely high debt‑to‑equity ratio. A discounted cash‑flow model values the stock at roughly four times its market price, indicating potential undervaluation, but the absence of earnings, dividends, and a volatile price history amplify the risk profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages suggests continued downside pressure
- Oversold RSI may produce a short‑term bounce
- High volatility could trigger rapid price swings
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- DCF fair value far exceeds current price, implying upside potential
- Strong revenue growth despite weak profitability
- Large cash reserves provide a cushion for restructuring
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Persistent negative earnings and high leverage raise sustainability concerns
- Potential regulatory headwinds in the specialty‑generic drug space
- Absence of dividend limits income‑focused appeal
Key Metrics & Analysis
Financial Health
Revenue Growth37.20%
Profit Margin-76.71%
ROE-33.90%
ROA0.50%
Debt/Equity33.37
Op. Cash Flow₩-155380320
Free Cash Flow₩6.0B
Industry P/E25.2
Technical Analysis
TrendBearish
RSI39.9
Support₩685.00
Resistance₩945.00
MA 20₩816.00
MA 50₩912.54
MA 200₩1,357.43
MACDBearish
VolumeStable
Fear & Greed Index75.07
Valuation
Fair Value₩3,413.66
GradeUndervalued
TypeValue
Risk Assessment
Beta0.49
Volatility64.68%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.